Data from the phase 3b STEP UP trial demonstrate that the 7.2 mg semaglutide dose provides superior weight reduction compared ...

First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total ...

Is it possible to train the body to resist seasonal allergies? That’s the hope promised by a new line of immunotherapy reviving an old treatment.

Glenis Scadding still remembers one of her first patients for sublingual immunotherapy, forty years later. His hay fever was ...

Good day, and thank you for standing by. Welcome to the Alvotech Q4 2025 and Full Year 2025 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being ...

One-year trial shows AVT05 golimumab biosimilar matches Simponi in rheumatoid arthritis, including switching, with comparable ...

The newly approved mosunetuzumab for relapsed/refractory follicular lymphoma improves clinic efficiency and patient ...

Setmelanotide receives FDA approval for acquired hypothalamic obesity based on phase 3 trial data demonstrating meaningful body mass index reductions.

Early data from the first phase III trial of Lilly’s triple agonist show reductions in weight and HbA1c for patients with ...

This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...

T he recent reimbursement of Bimzelx (bimekizumab) in Ireland represents an important step forward in access to treatment for people living with immune-mediated diseases, includin ...

Novo Nordisk today announced US Food and Drug Administration (FDA) approval of a new higher dose of Wegovy®, Wegovy® HD (semaglutide) injection 7.2 mg, which demonstrated substantial weight loss in ...